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Summary 
We have previously described a set of mutants (16.23-selected  mutants) of a B lymphoblastoid 
cell line that are defective in the presentation of intact proteins to class II-restricted T cells, but 
effectively  present immunogenic peptides. The mutations in these mutants are recessive in somatic 
cell hybrids and are not in Class II structural genes. Here, we report on a unique mutant, 5.2.4, 
in which a similar defect in class II-restricted antigen presentation has occurred in association 
with a one-megabase homozygous deletion in the class II region of the major histocompatibility 
complex (MHC). The defects in class II presentation among three of the 16.23-selected mutants, 
and between these mutants and 5.2.4, are noncomplementary in somatic cell hybrids. This suggests 
that the class II presentation-defective phenotype in all four mutants results from lesions in a 
single MHC-linked gene, a conclusion strengthened by the finding that in a hybrid made with 
a second, unrelated MHC deletion mutant, T2, the class II presentation defect in a 16.23-selected 
mutant is also not complemented. Mutant 5.2.4, in addition to its class II presentation defect, 
is also defective in surface expression of MHC class I molecules, most likely because its deletion 
encompasses the peptide supply factor 1 gene, whose function is known to be required for normal 
abundance of cell surface class I molecules. However, the surface abundance of class I molecules 
is normal in the 16.23-selected mutants, suggesting that the lesions affecting class I surface abundance 
and class II presentation result from mutations in different genes. 
p resentation of an endocytosed protein antigen by APC 
requires that it be processed intracellularly into immuno- 
genic peptide fragments, which become bound to MHC class 
II molecules (reviewed in reference 1). The complex of pep- 
tide and MHC molecule is transported to the APC surface, 
where it can be recognized by CD4 + T cells. This handling 
of foreign antigen is apparently part of a more general pro- 
cess in which class II molecules en route to the cell surface 
bind both foreign and self peptides. The majority of cell sur- 
face class  II  molecules are  occupied by  self-peptides  (2). 
Nonetheless, this system provides effective immune surveil- 
lance of the extraceUular space, because occupancy of a small 
fraction of MHC class II molecules with immunogenic pep- 
tide is sufficient to activate specific T  cells  (3,  4). 
Previously, we used an anti-HLA-DK3  mAb,  16.23,  to 
select a set of B-lymphoblastoid mutants (hereafter called 16.23- 
selected mutants) which define a novel step in class II-re- 
stricted antigen presentation (5, 6). Unlike the progenitor 
cells, the mutants, exemplified by mutant 9.5.3,  are unable 
to stimulate specific T cell clones when exposed to intact pro- 
tein antigens. Their class II molecules effectively present ex- 
ogenously supplied peptides, however. Thus, the mutants ap- 
pear  unable  to  form  intracellular  MHC  class  II-peptide 
complexes from intact protein antigens. The class II struc- 
tural genes and the surface abundance of class II molecules 
in these mutants are normal. However, the mutants demon- 
strate a subtle change in class II molecule conformation. Their 
HLA-DK3 molecules have lost expression of the epitope rec- 
ognized by antibody 16.23, and dass II dimers extracted from 
the mutants dissociate into monomers in SDS-PAGE, whereas 
dimers extracted from progenitor cells under the same con- 
ditions do not dissociate.  We have proposed that these con- 
formational changes are related to underoccupancy of cell sur- 
face class II molecules resulting from defective  peptide loading 
during class II molecule biosynthesis. The amount of invar- 
iant chain (Ii), 1 its glycosylation, and the kinetics of its as- 
sociation and dissociation from DR molecules do not differ 
in mutant 9.5.3 and its progenitor, 8.1.6 (reference 6 and E. 
1  Abbreviations used in thispaper: B-I.CL, B lymphoblastoid cell line; EMS, 
ethylmethane sulfonate; HBsAg, hepatitis B surface antigen; li, invariant 
chain;  PSF1, peptide supply factor 1; TT, tetanus toxin/toxoid. 
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DR-Ii complexes in the mutants traffic normally through the 
Golgi apparatus to the compartment where Ii dissociation 
occurs. The phenotypic features of the mutants thus impli- 
cate gene products other than class II molecules and Ii in 
the formation of MHC class II-peptide complexes. 
Here, we report on an informative new mutant B lym- 
phoblastoid cell line (B-LCL), 5.2.4, which was selected with 
an anti-DR mAb for loss of surface expression  of DR mole- 
cules.  In contrast to the 16.23-selected  mutants, which are 
likely to be point mutants (reference 7 and D. Pious, unpub- 
lished data), mutant 5.2.4 has a homozygous deletion within 
the class II region of the MHC. Mutant 5.2.4 resembles the 
unrelated mutant human cell lines,  721.174 and T2 (8-10), 
and the mutant murine line RMA-S (11) in that it has re- 
duced surface abundance of class I molecules that can be in- 
creased by incubation of the cells with an appropriate pep- 
tide. However, 5.2.4 is unlike 721.174 and T2 in that it retains 
DP genes from one haplotype, allowing us to examine the 
function of its class II molecules. We find that deletion mu- 
tant 5.2.4 manifests the class II presentation-defective  pheno- 
type, and it is noncomplementary with several of the 16.23 
selected mutants for the class II presentation defect. Further, 
the T2 cell line, which is homozygously deleted for a region 
of the MHC that includes the 5.2.4 deletion, does not com- 
plement the mutation in 9.5.3. These findings strongly sug- 
gest that defects in a gene(s) mapping within the MHC are 
responsible  for the class II presentation-defective phenotype. 
Materials and Methods 
APC Lines.  With the exception of the T2 cell line, the APC 
used in these studies are all derived from B-LCL T5-1 (Fig. 1 a). 
The hemizygous deletion mutants 8.1.6 and 9.28.6 were derived 
directly from T5-1, 8.1.6, by ethyl methane sulfonate (EMS) muta- 
genesis of T5-1 and selection with an HLA-DR1 antiserum and 
complement (12), and 9.28.6, by mitomycin c mutagenesis and se- 
lection with an HLA-B8 antiserum, 0800 (13). The deletion break- 
points in 8.1.6 and 9.28.6 were defined by Southern blot analyses, 
as described (14). To derive mutant 5.2.4, 8.1.6 was mutagenized 
with EMS and selected with a monomorphic anti-DR antibody, 
VI.15, and complement. Presentation-defective  mutants 9.5.3, 7.9.6, 
and 7.2.6 were also isolated from 8.1.6, after EMS mutagenesis 
and immunoselection with mAb 16.23 plus complement (see ref- 
erence 5 for details). 3.1.3 is a DR-null cell line derived from 3.1.0, 
a hemizygous  MHC-deletion mutant, which lacks the entire MHC 
of the DQ2/DR3 haplotype (14). 3.1.3 expresses DQ1 and DP4.1. 
9.22.3 is a DR-null cell line, derived from 8.1.6 by deletion of the 
single DRA gene in 8.1.6 (5). Mutant 721.174, derived  from B-LCL 
721, bears a homozygous deletion that extends from telomeric to 
the DPA2 locus to between DRA and the complement gene cluster 
(8). T1 is a somatic cell hybrid of 721.174 and the T cell line, CEM. 
A derivative of T1, (T2) was selected for loss of both copies of 
human chromosome 6 provided by CEM (9). T2 ceils expressing 
transfected  DRA and DRBI*0408 cDNAs (T2-DR) were provided 
by W. Kwok. The cDNAs were introduced in retroviral vectors, 
as described (15). 
T Cells and T  Cell Proliferation Assays.  The generation of the 
hepatitis B  surface antigen  (HBsAg)-specific T  cell clone and 
identification of a stimulatory oligopeptide Sla (amino acid posi- 
tion 14-33) have  been described  (6). The polyclonal  T cell line specific 
for tetanus toxoid (TT) was generated as described (16). The im- 
munogenic peptide derived from tetanus toxin (amino acid posi- 
tion 947-969) has been described (17). It was found to be restricted 
by DP4.1 in  T5-1 and its derivatives by analysis with class II 
molecule-loss mutants of T5-1 (18). For assay, 2 x  104 T cell blasts 
were cocultured with 1-2  x  10  s mitomycin-c-treated  B-LCLs as 
APCs in the presence or absence of  either native  antigen or immuno- 
genic peptide. T cell stimulation was measured  by incorporation of 
[3H]thymidine  into DNA (cpm in the presence of antigen -  cpm 
in the absence of antigen). Recombinant HBsAg, the gift of  Merck, 
Sharp, and Dohme (West Point, PA), was used at 10/~g/ml; syn- 
thetic HBsAg peptide Sla was used at 1/~g/ml or at varied concen- 
trations, as indicated. Purified TT (Massachusetts Department of 
Public Health, Jamaica Plain, MA) was used at 5/xg/ml; TT pep- 
tide was used at 10 #g/ml. 
Somatic Cell Hybrids.  For somatic cell hybridization, dominant 
selectable markers were introduced  into 9.5.3, 7.9.6, 7.2.6, and 5.2.4. 
An Escherichia coli gpt gene, conferring resistance to mycophenolic 
acid, was transfected into 9.5.3, 7.9.6, and 7.2.6 by electropora- 
tion.  The  dihydrofolate reductase gene, conferring resistance to 
methotrexate, was introduced into 5.2.4, 7.9.6, and 7.2.6 by cocul- 
ture  with  PA317-SDHT, a  retrovirus-packaging fibroblast line, 
provided by A.  Dusty Miller (19). T2-DR cells containing the 
hygromycin  b phosphotransferase  gene were kindly provided by W. 
Kwok (Virginia Mason Research Center, Seattle, WA). Somatic  cell 
hybrids were prepared by polyethylene  glycol (PEG) fusion, as de- 
scribed (6). Each hybrid  contains  both selectable  markers by Southern 
blot analysis  (not shown). The tetraploid status of selected hybrids 
was also confirmed  by DNA content determination  using propidium 
iodide staining, FACScan  |  (Becton Dickinson Immunocytometry 
Sys., Mountain View, CA) analysis, and CELLFIT  # software (not 
shown). 
Immunofluorescent Flow Cytometry.  Immunofluorescent  analysis 
was carried out using the following  fluoresceinated  antibodies: mAb 
16.23, anti-DR3 (20); mAb VI.15, anti-DR dimer (13); or unla- 
beled primary antibodies: mAb ME-l, anti-HLA-B27 (21); mAb 
PA2.1, anti-HLA A2 (22), followed  by fluoresceinated  goat F(ab)2 
anti-mouse IgG (H+L) (Tago, Inc., Burlingame,  CA). In all assays, 
binding of FITC-labeled goat anti-mouse antibody (GAM) alone 
was used as control for autofluorescence.  Binding to class I-nega- 
tive Daudi cells (23) was used as a negative control, when appro- 
priate. For antibody binding, cells were incubated with saturating 
amounts of FITC-conjugated antibody, or unlabeled antibody fol- 
lowed by FITC-labeled GAM. Labeled  cells were washed and ana- 
lyzed on a FACScan  |  (Becton Dickinson & Co.). Cell number is 
displayed against a 4 log unit axis of fluorescence intensity (17 
channels equals a doubling of intensity). 
Induction of HLA-B27 Cell Su~ce Expression.  Cells  (3 x l@/ml) 
were exposed to medium (RPMI 1640 plus 10% FCS) plus DMSO 
(0.5%) alone or medium plus DMSO and either the HLA-B27- 
restricted peptide of the HIV-1 gag protein (amino acids 265-279) 
(24) or Sla, the FILA-DP4-restricted  peptide of  HBsAg (amino  acids 
14-33), as a negative control. Both peptides were used at a concen- 
tration of 50 ~tg/ml. Incubation was for 48 h at 37~  5  x  10  s 
cells were harvested and stained by indirect immunofluorescence 
with mAb ME-l, followed  by FITC-labeled GAM. Samples were 
analyzed on a FACScan  |  (Becton Dickinson & Co.). 
Dimer Stability Assay.  This assay  has been described  (5). Briefly, 
unboiled,  whole-cell NP-40 extracts were  analyzed by  one- 
dimensional SDS-PAGE and immunoblotted  with monoclonal 
HB10.A, which reacts with DRB chains as monomers and as 
1608  Major  Histocompatibility  Complex-linked  Antigen Presentation Function DRc*/3 dimers (25). The stability of HLA dass II dimers to SDS 
without boiling or reduction has been described (26). 
Southern Blot Analyses.  These analyses were performed as de- 
scribed (14). 
Results 
Mutant 5.2.4 Has a Homozygous Deletion within the Class 
II Region of the MHC.  The progenitor of both the newly 
isolated mutant 5.2.4 and of the 16.23 sdected mutants (e.g., 
9.5.3) was 8.1.6, which in turn was isolated from the B lym- 
phoblastoid line T5-1 (Fig. 1 a). 8.1.6 has a hemizygous de- 
letion of its MHC DQ1/DR1 haplotype whose breakpoints 
map telomeric of the DP genes and centromeric of the C4 
genes (14). More precise mapping of the deletion breakpoints 
(Fig. 1 b) demonstrates that the Xl-6 genes located immedi- 
ately centromeric of the 21-OHB gene, and the Y4 and Y5 
genes located telomeric of the DNA gene, lie outside the 
8.1.6 deletion and thus delimit its centromeric and telomeric 
breakpoints (27). Mutant 5.2.4 has undergone a second dele- 
tion, in MHC haplotype DQ2/DR3. From serological anal- 
yses (data not shown) the second ddetion appears to have 
removed the entire MHC of the DQ2/DR3 haplotype. This 
was confirmed by Southern blot analyses, which indicate that 
5.2.4 has a homozygous deletion of the DR/DQ region and 
a hemizygous deletion of DP and class I genes (Fig.  1 c). 
Class II-restricted Antigen Presentation Is Impaired in Mutant 
5.2.4.  To evaluate the ability of 5.2.4 to present class II-re- 
stricted antigens to T cells, we studied its ability to present 
HBsAg to a specific, DP4-restricted T  cell clone.  Soluble 
HBsAg must be processed to yield the epitope recognized 
by these T cells and a synthetic peptide corresponding to amino 
acids 14-33 of HBsAg (Sla) is also stimulatory for this clone 
(6). We compared presentation of HBsAg by 5.2.4 to that 
of its progenitor, 8.1.6,  and to a DP-hemizygous cell line, 
9.28.6 (see Fig.  1 a), the latter to control for any effect of 
the DP gene dosage difference between 8.1.6 (dizygous) and 
5.2.4 (hemizygous). The progenitor line, 8.1.6, and the 9.28.6 
control line effectively present both native HBsAg and the 
synthetic peptide corresponding to the HBsAg epitope (Fig. 
2 a).  In contrast, mutant 5.2.4 is defective for presentation 
of the native antigen, but effectively presents the HBsAg pep- 
tide. Likewise, presentation of native TT is defective in 5.2.4, 
whereas a DP-restricted TT peptide is presented normally 
(Fig. 2 a). These results indicate that mutant 5.2.4 has a de- 
fect resembling that found in the previously characterized 
16.23-selected mutants in that it is defective for presentation 
of intact protein antigens to class II-restricted T  cells, but 
effectively presents the peptide epitope from those antigens. 
Both 16.23 Selected Mutants and 5.2.4 Have an Enhanced Ca- 
pacity to Present Peptide Antigen.  We have hypothesized that 
the altered conformation of cell surface class II molecules in 
the 16.23-selected mutants reflects reduced occupancy of their 
peptide-binding grooves (6). To evaluate the possibility that 
the binding grooves of the DP molecules expressed by 5.2.4 
are empty or under-occupied, we compared the ability of 5.2.4 
and a control DP hemizygous line,  9.28.6,  to stimulate a 
specific T cell response over a range of concentrations of pep- 
tide antigen. Mutant 5.2.4 shows an "~15-fold enhancement 
in HBsAg peptide presentation compared with 9.28.6 (Fig. 
2 b). Presentation by 5.2.4 of another DP-restricted peptide, 
amino acids 94%969 of TT, is also enhanced to a similar de- 
gree (T. Monji, data not shown). Mutants 9.5.3, 7.9.6, and 
7.2.6, representative of the 16.23-selected mutants, also show 
enhanced presentation of the DP-restricted HBsAg peptide, 
compared with progenitor 8.1.6 (Fig. 2 c). Thus, both 5,2.4 
and the set of mutants represented by 9.5.3  present DP- 
restricted peptides more effectively than wild-type cells. These 
results are consistent with the hypothesis that these mutants 
bind class U-restricted peptides more avidly than the pro- 
genitor because the binding grooves of their class II dimers 
are empty or underoccupied with self-peptides. 
MHC Deletion Mutant 5.2.4 Is Noncomplementary with the 
I6.23 Selected Mutant 9.5.3.  To evaluate the possibility that 
the gene responsible  for the class II presentation defect in 
the homozygous deletion mutant 5.2.4 is the same as that 
altered in mutant 9.5.3, we made a somatic cell hybrid be- 
tween 5.2.4 and 9.5.3 and assayed the hybrid for complemen- 
tation of the mutant phenotype. To assess complementation, 
we examined the conformational state of the DR molecules 
expressed by the 5.2.4  x  9.5.3 hybrid. In two independent 
hybrids, the DR molecules retain the mutant phenotype: the 
hybrids fail to bind the 16.23 antibody (Fig. 3 a), and ex- 
tracted DR dimers from the hybrids dissociate into monomers 
in SDS-PAGE (Fig. 3 b). Thus, the conformational defect in 
the DR molecules expressed by 9.5.3 is not restored by hy- 
bridization with 5.2.4.  These hybrid cells are also impaired 
for presentation of intact TT, but effectively present a DP- 
restricted peptide derived from TT (Fig. 3 c). By these three 
criteria, therefore, the hybrids made between 9.5.3 and 5.2.4 
maintain the mutant phenotype. Further, as the lesions in 
both 9.5.3 and 5.2.4 act as recessives in somatic call hybrids 
(see Table 1), the mutant phenotype of the 9.5.3  x  5.2.4 
hybrid indicates  that the mutations affecting class II mole- 
cules in 9.5.3 and 5.2.4 are noncomplementary. Thus, it ap- 
pears that the same gene is defective in both cells, making 
it likely that the relevant  gene is MHC linked. 
T2, a Second Homozygous MHC Deletion Mutant, Is Also 
Noncomplementary with 9.5.3.  It was formally possible that 
a second mutation in 5.2.4, in addition to its MHC deletion, 
was responsible for the class II presentation defect in mutant 
5.2.4 and for its lack of complementation  with mutant 9.5.3. 
To address this possibility,  we utilized T2, a class II-nega- 
tire, MHC deletion mutant not related to 5.2.4, but with 
a slightly larger homozygous deletion that includes that of 
5.2.4 (references 9, 27). We first asked whether class II mole- 
cules introduced into T2 by transfection manifest the mu- 
tant phenotype. This proved to be the case; DR molecules 
in a T2-DR transfectant are expressed stably as dimers at the 
cell surface (Fig. 3 a) but dissociate into monomers in SDS- 
PAGE (Table 1). Second, we made a somatic cell hybrid be- 
tween mutant 9.5.3 and the T2-DR transfectant. The DR3 
molecules expressed by this hybrid retain the mutant pheno- 
type, as they fail to regain binding of the 16.23 mAb (Fig. 
1609  Mellins  et al. Figure 1.  (a) Derivation of mutants 8.1.6,  9.28.6,  and 5.2.4  from cell line T5-1.  Extended MHC haplotypes are shown.  The vertical bars indicate 
the approximate chromosomal locations of the genetic loci (e.g., DRA and DRB) encoding each of the expressed proteins. (b) Genetic map of the 
relevant portion of the MHC class II and class 111 regions with delineation of 8.1.6 deletion breakpoints. Scale in kb.  (Adapted from (reference 27) 
with permission copyright (c), 1990 Macmillan Magazines Ltd.). (c) Mutant 5.2.4 has a deletion within the class II region of the MHC. Hindlll-digested 
DNA from 5.2.4 and progenitor T5-1  (see Fig.  1 a) was analyzed by Southern blotting, using the following cDNA probes: DPB1  (31, 32); DPA1 
(33); DQA1 (34); DQB1  (34); DRB3 (35); DRA (36); C4 (37); and HLA 1.3, an HLA-B7 class I gene (38).  Representative  blots, which define the 
extent of the homozygous deletion in mutant 5.2.4,  are shown. (DPA) Southern blots of T5-1 DNA probed with DPA cDNA have two major bands 
and two weak bands,  all of which are reduced in intensity ('~50%) in 5.2.4.  These findings indicate the loss of DPA genes of one haplotype. (DQA) 
The DQA1 cDNA clone hybridized with two DQA-like genes  (34) which are represented  by 7.9-,  6.0-, and 2.7-kb bands in T5-1 DNA. The 7.9- 
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Figure 2.  Antigen presentation  by DP molecules is altered in mutant 
5.2.4.  (a) Proliferation  of antigen-specific T cells stimulated  with native 
antigen or immunogenic peptide,  presented  by progenitor  8.1.6, DP- 
hemizygous line, 9.28.6 (see Fig. 1 a), and mutant 5.2.4. T calls are DP4- 
restricted and specific for HBsAg or TT. T cell stimulation was measured 
by [3H]thymidine  incorporation as described (16). Data are expressed as 
percent of stimulation  by 9.28.6 and are median values from triplicate cul- 
tures of a representative experiment;  SEM <15% in at least three experi- 
3 a). These findings confirm the conclusion that a gene respon- 
sible for the class II presentation-defective phenotype maps 
within the one-megabase MHC  region deleted in mutant 
5.2.4,  and, pari passu, within the larger deletion in T2. 
The Defects in Mutant 9.5.3, Z2.6, and 7.9.6 Are Noncom- 
plementary.  The phenotype of the 16.23-selected  mutants 
might result from lesions in different genes, each of which 
is required for the intracellular formation of class II mole- 
cule-peptide complexes. To investigate this, we made a series 
of somatic cell hybrids between independently arising 16.23- 
selected mutants (5, 6). To assess complementation, we mea- 
sured binding of the 16.23 antibody and the stability of DR 
dimers in SDS-PAGE.  We first determined that the genetic 
lesions in mutants 7.9.6 and 7.2.6 are recessive. Somatic cell 
hybrids made between these mutants and nonmutant B-LCLs 
have stable DR dimers and bind mAb 16.23 (Table 1). The 
mutation in 9.5.3 is also recessive (Table 1 and reference 6). 
The 9.5.3  x  7.2.6 hybrid, the 9.5.3  x  7.9.6  hybrid, and 
the 7.2.6  x  7.9.6 hybrid all retain the mutant phenotype 
for DR dimer stability (Table 1), suggesting that these mu- 
tants constitute a single complementation group.  None of 
these hybrids have regained normal binding of mAb 16.23 
(Table  1).  It thus appears  that a single,  MHC-linked gene 
is responsible for the class II presentation-defective pheno- 
type in mutants 9.5.3,  7.9.6,  and 7.2.6. 
Cell Surface Expression of Class I MHC Molecules Is Reduced 
in Mutant S.2.4, but Not in16.23 Selected Mutants.  AnMHC- 
linked gene, peptide supply Factor 1 (PSF1),  is implicated 
in the control of cell surface abundance of class I MHC mol- 
ecules (27,  28).  In mutant cells that lack mRNA for this 
ments.  Stimulation of HBsAg-specific T cells by 9.28.6 with intact  pro- 
tein, 29,147 cpm; with peptide,  63,654 cpm; stimulation  of TT-specific 
T cells by 9.28.6 with intact protein, 9,305 cpm, with pepfide, 9,063 cpm. 
The modest T cell stimulation  in response to 5.2.4 cells exposed to intact 
antigen may be due to the fact that  the 5.2.4  mutation is "leaky;' i.e., 
some class II/peptide complexes form in 5.2.4, despite deletion of the rele- 
vant gene. Alternatively, the whole antigen preparations may contain small 
amounts  of denatured  or fragmented  antigen which can be presented 
without further processing. For the polyclonal TT-specific T cell line, a 
third possibility is that the line includes a subpopulation  of T cells respon- 
sive to complexes generated in a pathway which is unaltered in 5.2.4. The 
response of this line is similar in magnitude to the response of other poly- 
donal T cell lines to the 16.23 mutants  (6). (b) Proliferation  of HBsAg- 
specific T  cells stimulated  with HBsAg peptide  at indicated  concentra- 
tions,  using 5.2.4  or 9.28.6  as APCs.  T  cell stimulation  was calculated 
as in (a). (c) Proliferation of HBsAg-specific T cells stimulated with HBsAg 
peptide  at  indicated  concentrations,  using  representative  presentation- 
defective mutants,  9.5.3, 7.9.6, 7.2.6, or progenitor 8.1.6 as APCs. T cell 
stimulation  was calculated as in (a). 
and 6.0-kb bands represent DQA1 alleles and the 2.7-kb band represents a DQAl-like sequence, DQA2 (14) which maps centromeric of both DQA1 
and DQB1.  All bands  are missing  in 5.2.4,  indicating  homozygous deletion  of DQA1 and DQA2. (DRA) T5-1 DNA digested  with HindIll and 
probed with DRA yields two bands. Both bands are absent in mutant 5.2.4, indicating homozygous deletion of DRA genes. (C4) The fourth component 
of the human complement system:  the two bands  detected  by the C4 cDNA in T5-1  DNA are reduced in intensity  and therefore  deleted  on one 
haplotype  in mutant 5.2.4.  The blots were also analyzed with the HLA-1.3 probe, which cross-hybridizes with a large number of class I sequences. 
There is a reduction  in intensity of •50%  in the class I bands from mutants 5.2.4 compared with T5-1, and a 5.8-kb band,  which represents a class 
I sequence of the DR3 haplotype (14), is missing in 5.2.4 DNA (not shown). These findings indicate deletion of class I sequences of the DR3 haplotype 
in mutant 5.2.4.  (li and Bzra) Blots were also analyzed with probes for these genes which are unlinked  to the MHC, as controls for amount of DNA 
loaded.  No differences between T5-1  and  5.2.4  DNA were observed (not shown). 
1611  Mellins  et al. Figure  3.  Somatic  cell  hybrids 
made between 9.5.3 and 5.2.4, and 
between 9.5.3  and T2 express the 
mutant phenotype.  (a) A 9.5.3  x 
5.2.4  hybrid binds mAb  16.23 at 
levels equivalent to mutant 9.5.3; a 
9.5.3  x  T2-DR hybrid binds the 
16.23 mAb at levels equivalent  to 
9.5.3  as well.  Immunofluorescent 
analysis was carried out using the 
following fluoresceinated antibodies 
and cells.  Control (  ),  goat 
anti-mouse antibody;  16.23,  anti- 
DR3, (---): (reference 20); VI.15, 
anti-DR dimer (...):(reference  13). 
All the curves for mutant 5.2.4 (b) 
are superimposed, as 5.2.4 expresses 
no cell surface DR. For T2-DR (d), 
the mAb  16.23 curve  is  superim- 
posed on the control antibody  curve. 
The T2-DR transfectant does  not 
bind the DR3-specific mAb 16.23, 
because the introduced  ~8 chain ex- 
presses  the  DR4  specificity.  The 
failure of the 9.5.3  x  T2-DR hy- 
brid to express the 16.23 epitope is 
not due to segregation  of the chro- 
mosome 6  encoding the DR3 B1 
gene,  because the hybrid expresses 
the HLA-B5 molecule (not shown) 
and HLA-B5 surface expression re- 
quires a functional  PSF1 gene (28), 
which must be contributed  by the 
(DR3+) chromosome 6 from mu- 
tant 9.5.3. (b) The HLA-DR dimers 
extracted from 9.5.3 and two inde- 
pendent  hybrids (9.5.3  x  5.2.4a, 
9.5.3  x  5.2.4b) dissociate into monomeric subunits in one-dimensional  SDS-PAGE. A Western blot analysis of detergent  (NP-40)  extracts of indicated 
cell lines, using mAb HB10A, is shown. (c) Proliferation of TT-specific T cells stimulated with native TT or TT peptide (947-969)  presented by progen- 
itor 8.1.6  and by the 9.5.3  x  5.2.4 hybrid. T cell stimulation was measured by [3H]thymidine incorporation.  Data are expressed as percent of stimula- 
tion by 8.1.6 and are median values from triplicate cultures of a representative experiment  (SEM <15%). Similar results were obtained in three experi- 
ments.  Stimulation of TT-specific T  cells by 8.1.6  with native TT,  10,534 cpm;;  with peptide  7,093  cpm. 
gene,  assembly  and  cell  surface  expression  of class  I mole- 
cules are defective, but can be restored  by incubation with 
peptides that bind to the class I molecules expressed  by the 
cell (27). Mutant 5.2.4,  which is homozygously deleted for 
PSF1,  shares this phenotype.  Its  surface level of HLA-A2 is 
reduced by ~50%  (Fig. 4 a) and that of HLA-B27 is reduced 
by m85%  compared to progenitor 8.1.6 (Fig. 4  b). Incuba- 
tion of 5.2.4 with peptides that bind to HLA-B27, HIV gag 
265-279 (Fig. 4 d), or influenza nucleoprotein 383-394  (not 
shown) enhances HLA-B27 cell surface expression two fold, 
whereas incubation with a DP-restricted peptide has no effect 
(Fig. 4 c).  In contrast, PSF1 function does not appear to be 
defective in mutants 9.5.3,  7.2.6,  and 7.9.6,  as evidenced by 
their normal cell surface levels of HLA-A2 and B27 (Fig. 4, 
a and b). Mutant  5.2.4  thus differs from the  16.23-selected 
mutants in the formation of intracellular complexes between 
class  I  molecules  and  peptides,  suggesting  that  lesions  in 
different  genes  underlie  the  class  I-  and  class  II-defective 
phenotypes  in mutant  5.2.4. 
Discussion 
In a previous study, we characterized  a set of mutants of 
an EB virus-transformed B cell line that are defective in their 
ability  to function as class  II-restricted antigen-presenting 
cells when exposed to intact exogenous antigens (16.23-selected 
mutants).  At that time, the genetic basis for the defect was 
not determined.  In the present study, we have explored the 
genetics of the class II presentation defect using a homozy- 
gous MHC deletion mutant,  5.2.4.  We were first led to in- 
vestigate class II-restricted presentation in 5.2.4 because the 
16.23-selected  mutants arose at a high frequency  (ml0 -4) in 
mutagenized cell line 8.1.6,  which has a hemizygous MHC 
deletion (see Fig.  1 a). The fact that no such mutants could 
be isolated from comparably mutagenized T5-1, the undeleted 
progenitor of 8.1.6,  (E. Mellins and D.  Pious,  unpublished 
results) implicated the region of the MHC which is hemizy- 
gous  in 8.1.6  and homozygously  deleted in 5.2.4  as a pos- 
sible locus  of the involved  gene. 
The phenotypic changes associated  with the presentation 
1612  Major  Histocompatibility Complex-linked Antigen Presentation  Function Table  1.  Summary of DR Diraer Stability and raAb 16.23 
Binding Assays in  T2-DR  Transfectant and in (Mutant x  Wild 
Type) and (Mutant  x  Mutant) Hybrids 
Dimer stability  16.23  binding 
T2-DR transfectant  -  0* 
Hybrids 
(Mutant  x  wild type) 
9.5.3  x  3.1.3 
5.2.4  x  8.1.6 
7.9.6  x  3.1.3 
7.2.6  x  9.22.3 
(Mutant  x  mutant) 
5.2.4  x  7.9.6 
5.2.4  x  7.2.6 
9.5.3  x  7.9.6 
9.5.3  x  7.2.6 
7.9.6  x  7.2.6 
+  + 
ND  + 
+  + 
+  + 
Dimer stability was determined in Western blot analyses, as in Fig. 3 B. 
Binding of mAb 16.23 was determined by FACS  |  analyses, as in Fig. 
3 A. For 16.23 binding,  +  signifies binding at >80%  of levels bound 
by 8.1.6, normalized for level of cell surface DR;  -signifies binding at 
levels equivalent to 16.23-selected mutants, which range from 0 to 20% 
of 8.1.6 levels. Cell lines 3.1.3 and 9.22.3  are both DR-null B-LCLs, 
which present  DQ- and DP-restricted antigens  normally (see Materials 
and Methods).  Data on the 9.5.3  x  3.1.3 hybrid have been previously 
reported (6). 
* T2-DR expresses the DR4 spedficity only and fails to bind the anti- 
DR3 mAb  16.23,  as expected. 
defect in the 16.23-selected  mutants, and the fact that 5.2.4 
retains expressed DPA and DPB genes, provided the means 
to assess this function in 5.2.4. Although 5.2.4 expresses DP 
molecules on the cell surface, it is defective in the presenta- 
tion of DP-restricted intact protein antigens to antigen-specific 
T cells. It presents DP-restricted antigenic peptides efficiently, 
however. In fact, in this study we show that both 5.2.4 and 
the previously isolated mutants present peptides more effi- 
ciently than does the progenitor. The enhanced presentation 
of peptides is consistent with the interpretation that class II 
molecules on the cell surface of these mutants are un- or un- 
deroccupied with self-peptides.  The fact that 5.2.4 had ac- 
quired the class II presentation defect which characterizes the 
previously isolated mutants coincidently with a homozygous 
MHC deletion further implicated the deleted region as the 
site of the involved gene. 
Given the phenotypic similarities of the defects in 5.2.4 
and the 16.23-selected  mutants, it became of interest to de- 
termine whether defects in the same or different genes un- 
derlie the presentation abnormalities. The result is dear: 5.2.4 
fails to complement three independently arising 16.23-selected 
mutants, and the latter fail to complement each other. This 
is consistent with the interpretation that all four mutants 
are defective in the same gene(s). Based on the complemen- 
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tation results and the association of the class II presentation 
defect in 5.2.4 with the homozygous deletion in the class 
II region, we tentatively concluded that the affected gene in 
all four mutants maps to the deleted region. However, it re- 
mained possible,  although unlikely, that 5.2.4 could have an 
occult second genetic lesion elsewhere in the genome that 
was responsible for its presentation defect, and that this gene 
was also defective in the 16-23-selected  mutants. If this were 
the case,  a  second,  independently arising  mutant  with  a 
homozygous deletion that includes the MHC deletion in 5.2.4 
should complement the class II presentation defect in the 16.23- 
selected mutants. T2 has a homozygous MHC deletion that 
includes that of 5.2.4. However, T2 failed to rescue the mu- 
tant phenotype in a hybrid between T2 and mutant 9.5.3, 
again consistent with the mapping of the presentation defect 
to the deletion. In addition, DR dimers expressed by a T2- 
DR transfectant demonstrate the in vitro instability charac- 
teristic of the class II mutant phenotype (Table 1), and DR3 
dimers expressed by a T2-DR3 transfectant fail to bind the 
16.23 antibody (P. Cresswell, personal communication). For 
these reasons we conclude that a gene(s) whose defect is respon- 
sible for the class II presentation abnormality in 5.2.4 and 
the 16.23-selected mutants maps to the MHC class II region. 
Within the 5.2.4 deletion implicated in the class II presen- 
tation defect, the only known genes, besides class II struc- 
tural genes, are a cluster of genes mapping between DNA 
and DOB (Fig.  1 b and reference 27).  Two of these, desig- 
nated Y1 and Y3, are homologous to bacterial transport and 
mammalian multi-drug resistance genes. The Y3 gene product, 
PSF1, is required for normal cell surface abundance of class 
I molecules. A  mutant, 721.134,  which lacks Y3 mRNA, 
has reduced surface levels of class I molecules and is com- 
plemented for this defect by transfection of an expressible 
Y3 gene (27, 28). However, a similar defect in class I mole- 
cule expression in the MHC deletion mutant 721.174 is not 
restored by transfection of Y3, suggesting that another gene(s) 
in this region is also required for normal cell surface expres- 
sion of class I molecules (28). Thus, the deletion of Y3, and 
possibly of this other unidentified gene(s), is likely to ex- 
plain the lowered cell surface level of class I molecules in mu- 
tant 5.2.4. 
Deletion of Y3 seems unlikely to explain the class II pre- 
sentation defect in 5.2.4,  however. The 16.23-selected  mu- 
tants 9.5.3, 7.9.6, and 7.2.6 are noncomplementary  with 5.2.4 
for the class II presentation defect, but they have normal sur- 
face abundance of class I molecules, indicating that their Y3 
genes are functioning normally. Abnormalities in the Y1 gene, 
which, like Y3, is homologous to transport genes, could ac- 
count for the defect in class II-restricted antigen presenta- 
tion in 5.2.4 and the 16.23-selected  mutants. If the class II 
presentation defect in these mutants were caused by defects 
in Y1, it would suggest that class II-restricted peptides must 
be transported across a membrane. Other candidate genes that 
might be defective in the class II presentation mutants in- 
clude two MHC-linked genes encoding the polymorphic 
subunits of an intracellular complex, low molecular weight 
polypeptide (LMP) (29). The biological function of the LMP 
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Figure 4.  Cell  surface expression ofdass I MHC mol- 
ecules is reduced on 5.2.4, but not on 9.5.3, and can be 
specifically induced on 5.2.4 by a class I-restricted pep- 
tide. (a) Mutants 5.2.4 and 9.5.3 and progenitor line 8.1.6 
were stained with HLA-A2-specific  antibody PA2.1 by 
indirect immunofluorescence.  Staining of  class 1-negative 
cell line, Daudi, is shown  as negative  control. 16.23-selected 
mutants, 7.2.6 and 7.9.6, bind mAb PA2.1 at levels  equiva- 
lent to that of mutant 9.5.3 (not shown). (b) Mutants 
5.2.4 and 9.5.3 and progenitor  line 8.1.6 were stained with 
HLA-B27-specific  antibody ME-1 by indirect immuno- 
fluorescence. Mutants 7.2.6 and 7.9.6 bind mAb ME-1 
at levels equivalent to that of mutant 9.5.3 (not shown). 
(c) 5.2.4 cells stained with ME-1 after incubation with 
HBsAg peptide Sla. HBsAg peptide Sla was used at 2.3 
x  10 -s M and at 3.5  x  10 -s M, with equivalent results. 
(d) 5.2.4 cells stained with ME-1 after incubation with 
I-IIV gag peptide. HIV gag peptide was used at 2.8  x 
10-s M. An equivalent induction of ME-1 binding to 
that observed  with the gag peptide was observed  after 5.2.4 
incubation with  another HLA-B27-restricted peptide, 
NP1, derived from residues 383-394 of the influenza 
nucleoprotein (not shown). No increase in ME-1  binding 
to progenitor 8.1.6 was observed after incubation with 
HLA-B27-restricted peptides (not shown). 
of the proteolytic proteosome complex (30). A final possi- 
bility is that the relevant gene is an as yet unrecognized gene 
mapping to the region encompassed by the 5.2.4 deletion. 
Our study has demonstrated for the first time that genes 
within the MHC other than the classical MHC structural 
genes are required for class II-restricted antigen presentation. 
These results, taken together with the recent finding of an 
MHC-linked function required for dass I-restricted presen- 
tation, yield an emerging picture of striking conservation of 
MHC linkage of genes involved in antigen presentation. 
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